Mechanistic insights into CLNS1A-mediated chemoresistance and tumor progression in non-small cell lung cancer
Cancer Letters · 2025
DOI: 10.1016/j.canlet.2025.217783 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Tong-You Wade Wei und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Applied Chemistry, National Chi Nan University, Nantou, Taiwan; Division of Cardiology, Department of Medicine, University of Californi…. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Lung Neoplasms, Chloride Channels, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
CLNS1A is a chloride channel protein and an essential component of the methylosome complex, which additionally comprises PRMT5 and MEP50. In this study, we investigated its contribution to lung cancer and its potential as a therapeutic target. Analysis of transcriptomic datasets and western blotting revealed that CLNS1A, PRMT5, and MEP50 were overexpressed in lung cancer tissues, with elevated CLNS1A expression correlating with poor patient survival. CLNS1A overexpression enhanced platinum clearance from cells, increased the IC50 values for chemotherapy, and improved cell survival. Conversely, the knockdown of CLNS1A increased drug accumulation, reduced survival, and increased sensitivity to chemotherapy. The 3W mutant, a chloride channel-defective variant with steric hindrance at key bottleneck residues, impaired chloride ion transport, thereby reducing drug resistance, migration, and anchorage-independent growth. Mechanistically, CLNS1A promotes drug efflux through its chloride channel activity and activates the FAK-SRC-RAC1 pathway to enhance motility and clonogenicity. It also facilitates PRMT5-mediated RUVBL1 methylation to support anti-apoptotic DNA damage response signaling. In vivo, CLNS1A overexpression accelerated tumor growth and reduced survival, whereas CLNS1A knockdown sensitized tumors to cisplatin, enhancing therapeutic efficacy. These findings suggest that CLNS1A is a potential biomarker and therapeutic target, and its inhibition offers a strategy to overcome drug resistance and limit the metastatic progression of lung cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Applied Chemistry, National Chi Nan University, Nantou, Taiwan; Division of Cardiology, Department of Medicine, University of California, La Jolla, San Diego, CA, USA. Electronic address: t1wei@health.ucsd…
- Division of Thoracic Surgery, Chung Shan Medical University Hospital, Taichung, Taiwan; School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
- Department of Chest Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; Doctoral Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan.
- School of Basic Medicine, JingGangShan University, Ji'an, China.
- Division of Thoracic Surgery, Chung Shan Medical University Hospital, Taichung, Taiwan.
- Institute of Population Sciences, National Health Research Institutes, Zhunan, Taiwan.
Zitieren
APA
Wei, T. W., Hsia, J. Y., Yang, T. Y., Huang, Y. X., Wang, G. Z., Liu, Y. C., Wang, Y. W., He, F., Chen, J. M., Zhao, G. J., Lyu, P. C., Su, L. J., Chiu, S. C., & Yu, C. R. (2025). Mechanistic insights into CLNS1A-mediated chemoresistance and tumor progression in non-small cell lung cancer. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217783
Vancouver
Wei TW, Hsia JY, Yang TY, Huang YX, Wang GZ, Liu YC, et al. Mechanistic insights into CLNS1A-mediated chemoresistance and tumor progression in non-small cell lung cancer. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217783
BibTeX
@article{Wei2025,
author = {Wei, Tong-You Wade and Hsia, Jiun-Yi and Yang, Tsung-Ying and Huang, Yu-Xu and Wang, Guo-Zhi and Liu, Yi-Chung and Wang, Yi-Wun and He, Fangzhou and Chen, Jo-Mei Maureen and Zhao, Guo-Jun and Lyu, Ping-Chiang and Su, Li-Jen and Chiu, Shao-Chih and Yu, Chang-Tze Ricky},
title = {Mechanistic insights into CLNS1A-mediated chemoresistance and tumor progression in non-small cell lung cancer},
journal = {Cancer Letters},
year = {2025},
doi = {10.1016/j.canlet.2025.217783}
}
EUVIMED